Eliminating hypoxic tumor cells improves response to PARP inhibitors in homologous recombination–deficient cancer models is a research paper published in Journal of Clinical Investigation (2021). On theSindex it has a DataRank of 0. It has been cited 39 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH Clinical Center
Grant: CA-67166,CA-198291,CA-197713,R01ES016486
National Institutes of Health
Grant: 5R01CA198291-02
Preclinical Testing of a Novel Therapy Targeting AXL in Advanced Kidney Cancer
National Institutes of Health
Grant: 5R01ES016486-15
Regulation of the DNA Damage Response
National Institutes of Health
Grant: 5P01CA067166-05
CORE--BIOSTATISTICS FACILITY
National Institutes of Health
Grant: 5R35CA197713-02
The Impact of Mitochondrial Repression and Lipid Accumulation by HIF on Tumor Growth
NCI NIH HHS
Grant: T32 CA009302
Cancer Research UK
Grant: 28736
NCI NIH HHS
Grant: R35 CA197713
NIH HHS
Grant: S10 OD026899
NCRR NIH HHS
Grant: S10 RR026338
Medical Research Council
Grant: MC_UU_00001/8
NCI NIH HHS
Grant: P30 CA124435
NIEHS NIH HHS
Grant: R01 ES016486
NCI NIH HHS
Grant: R01 CA198291
NCI NIH HHS
Grant: P01 CA067166
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals